Kingdon Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kingdon Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-400,000	Closed	-$5.91M	–	149
2017 Q1	$5.91M	Sell	400,000 -4,103,900	-91%	-$66.5M	0.32%	67
2016 Q4	$72.9M	Buy	4,503,900 +853,200	+23%	+$15.5M	3.52%	3
2016 Q3	$66.2M	Buy	3,650,700 +1,693,200	+86%	+$33.1M	3.03%	5
2016 Q2	$32.2M	Buy	1,957,500 +1,082,500	+124%	+$17.5M	1.77%	14
2016 Q1	$14.5M	Sell	875,000 -535,000	-38%	-$9.36M	0.8%	38
2015 Q4	$30.6M	Sell	1,410,000 -695,000	-33%	-$13.5M	1.49%	18
2015 Q3	$41.7M	Buy	2,105,000 +1,205,000	+134%	+$38.1M	2.01%	10
2015 Q2	$31.3M	Sell	900,000 -350,000	-28%	-$10.7M	1.22%	18
2015 Q1	$32.5M	Buy	1,250,000 +950,000	+317%	+$17.4M	1.38%	12
2014 Q4	$3.87M	Sell	300,000 -900,000	-75%	-$11.3M	0.17%	115
2014 Q3	$14.7M	Buy	+1,200,000	New	+$13.9M	0.66%	41

Other funds holding HZNP

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Kingdon Capital Management's HZNP Position: Q2 2017 in Review

Kingdon Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 2,959,258 shares — an estimated $43.7M sold.

Kingdon Capital Management first reported a position in HZNP in Q2 2013 and held it in 16 quarters. The position peaked at $124M in Q3 2016. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

Kingdon Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Kingdon Capital Management sold 2,959,258 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $43.7M.
Kingdon Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 16 quarters.
Kingdon Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $124M in Q3 2016.
190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on Kingdon Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.